For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Nootropic & Cognitive · Comparison

Colostrinin vs Noopept

A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

ColostrininNoopept
CategoryNootropic & CognitiveNootropic & Cognitive
Also known asPRP (proline-rich polypeptide), ND, colostrum neuropeptide, CLN, ovine proline-rich polypeptideGVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl Ester
EvidenceResearch-stageResearch-stage
Dosing range100mcg–400mcg mcg, sublingual, on a 3 days on / 3 days off cycle5mg–20mg mg, 1–3x daily oral or sublingual (8–12 week cycles)
AdministrationSublingual tablet/dropOral (capsule/powder), Sublingual (dissolved under tongue), Intranasal
Key side effectsGenerally well-tolerated, Mild GI discomfort, Rare hypersensitivity (relevant for dairy protein sensitivity), Mild fatigue (initial days)Headache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day)
Cited sources2 references2 references

Key differences

  • Administration: Colostrinin — Sublingual tablet/drop; Noopept — Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal.
  • Dosing units differ: Colostrinin is dosed in mcg, Noopept in mg — they operate at different scales.
  • Frequency: Colostrinin is typically sublingual, on a 3 days on / 3 days off cycle; Noopept is 1–3x daily oral or sublingual (8–12 week cycles).

How each works

Colostrinin

Colostrinin modulates dendritic cell maturation and shifts cytokine balance toward anti-inflammatory patterns (reduced IL-6, TNF-α; increased IL-10). In neurological models, it reduces amyloid-β aggregation, decreases oxidative stress, and upregulates NGF while modulating the HPA axis stress response. A Polish double-blind trial showed statistically significant cognitive stabilization in mild-to-moderate AD patients over 15 weeks.

Noopept

Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.

Read the full Colostrinin profileRead the full Noopept profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.